← brief for 2026-08-10 · Slowing decline

Treatment outcomes and safety of telitacicept in reducing proteinuria and hematuria for refractory childhood IgA vasculitis nephritis

Key takeaways

This looked at a drug called telitacicept in children with a hard-to-treat kidney inflammation (IgA vasculitis nephritis). It tracked whether the drug lowered protein and blood in the urine, which are signs of kidney damage. It followed patients given the drug rather than running a randomized trial, so it shows a link, not firm proof.

Who did this work

Yue Xi (Beijing Children’s Hospital) · Nan Zhou (Beijing Children’s Hospital) · Qiang Sun (Beijing Children’s Hospital) · Chen Ling (Beijing Children’s Hospital) · Ying Liang (Beijing Children’s Hospital) · Lei Lei (Beijing Children’s Hospital) · Dan Wu (Beijing Children’s Hospital) · Zeping Cao (Beijing Children’s Hospital) · Xin Mo (Beijing Children’s Hospital) · Zhi Chen (Beijing Children’s Hospital)

Source

Indexed paper · OpenAlex — CKD concept sweep (DB seed + weekly delta) · 2026-08-08
https://doi.org/10.1186/s40001-026-04954-0